• 1
    Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians and blacks: an analysis of California cancer registry data. Cancer Causes Control 1997; 8: 24652.
  • 2
    Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84glu variant of the melanocortin-1 receptor is associated with melanoma. Hum Mol Genet 1996; 5: 16636.
  • 3
    Kennedy C, ter Huurne J, Berkhout J, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MCR1) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117: 294300.
  • 4
    Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas, but mutations in the CDK2NB, CDK2NC, CDK4 and P53 genes are rare. Int J Cancer 2001; 95: 38893.
  • 5
    Winsey SL, Haldar NA, Marsh HP, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60: 56126.
  • 6
    Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. Br J Cancer 1995; 72: 3246.
  • 7
    Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 6: 498504.
  • 8
    Strange RC, Ellison T, Ichii-Jones F, Bath J, Hoban P, Lear JT, Smith AG, Hutchinson PE, Osborne J, Bowers B, Jones PW, Fryer AA. Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999; 9: 26976.
  • 9
    Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994; 59: 5103.
  • 10
    Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 1998; 52: 6773.
  • 11
    Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immunity 2001; 2: 2531.
  • 12
    Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immunity 2002; 3: 22932.
  • 13
    Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397401.
  • 14
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
  • 15
    MacKie R, Hunter JA, Aitchison TC, Hole D, Mclaren K, Rankin R, Blessing K, Evans AT, Hutcheson AW, Jones DH. Cutaneous malignant melanoma, Scotland, 1979–89. The Scottish Melanoma Group. Lancet 1992; 339: 9715.
  • 16
    Adam Z, Adany R, Ladanyi A, Timar J, Balazs M. Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p. Clin Exp Metastasis 2000; 18: 295302.